{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:11:13Z","timestamp":1791443473681,"version":"4.3.3"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Baricitinib, a selective inhibitor for janus kinase (JAK) 1 and JAK2, is approved for use in rheumatoid arthritis. Systemic lupus erythematosus (SLE) is recently regarded as a potential candidate targeted by JAK inhibitors because of the relationship between its pathogenesis and JAK\/signal transducer and activator of transcription (STAT) pathway-mediated cytokines such as type I interferons. The objective of this study was to determine whether baricitinib could effectively ameliorate SLE using a murine model<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To investigate effects of baricitinib on various autoimmune features, especially renal involvements in SLE, eight-week-old MRL\/Mp-<jats:italic>Fas<jats:sup>lpr<\/jats:sup><\/jats:italic> (MRL\/<jats:italic>lpr<\/jats:italic>) mice were used as a lupus-prone animal model and treated with baricitinib for eight weeks. Immortalized podocytes and primary podocytes and B cells isolated from C57BL\/6 mice were used to determine the <jats:italic>in vitro<\/jats:italic> efficacy of baricitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baricitinib remarkably suppressed lupus-like phenotypes of MRL\/<jats:italic>lpr<\/jats:italic> mice, such as splenomegaly, lymphadenopathy, proteinuria, and systemic autoimmunity including circulating autoantibodies and pro-inflammatory cytokines. It also modulated immune cell populations and effectively ameliorated renal inflammation, leading to the recovery of the expression of structural proteins in podocytes. According to <jats:italic>in vitro<\/jats:italic> experiments, baricitinib treatment could mitigate B cell differentiation and restore disrupted cytoskeletal structures of podocytes under inflammatory stimulation by blocking the JAK\/STAT pathway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present study demonstrated that baricitinib could effectively attenuate autoimmune features including renal inflammation of lupus-prone mice by suppressing aberrant B cell activation and podocyte abnormalities. Thus, baricitinib as a selective JAK inhibitor could be a promising therapeutic candidate in the treatment of SLE.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.704526","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:49:03Z","timestamp":1629719343000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus"],"prefix":"10.3389","volume":"12","author":[{"given":"Jaeseon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Gwang","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Min","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seok","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungYe","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and Consequences of Jak-STAT Signaling in the Immune System","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase Inhibition in Autoimmunity and Inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic Lupus Erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus Nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I Interferon in the Pathogenesis of Lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311409963","article-title":"Possible Role of the JAK\/STAT Pathways in the Regulation of T Cell-Interferon Related Genes in Systemic Lupus Erythematosus","volume":"20","author":"Kawasaki","year":"2011","journal-title":"Lupus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells8080898","article-title":"Pathogenic and Therapeutic Relevance of JAK\/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition With an Oral Agent","volume":"8","author":"Alunno","year":"2019","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The Jakinibs in Systemic Lupus Erythematosus: Progress and Prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.39818","article-title":"Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31363-1","article-title":"Baricitinib for Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-Inhibitors. New Players in the Field of Immune-Mediated Diseases, Beyond Rheumatoid Arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatol (Oxf)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216571","article-title":"Efficacy of JAK 1\/2 Inhibition in the Treatment of Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus","volume":"79","author":"Maeshima","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3915","article-title":"IL-12 Deficiency in MRL-Fas(lpr) Mice Delays Nephritis and Intrarenal IFN-Gamma Expression, and Diminishes Systemic Pathology","volume":"170","author":"Kikawada","year":"2003","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0065-2776(08)60342-9","article-title":"Murine Models of Systemic Lupus Erythematosus","volume":"37","author":"Theofilopoulos","year":"1985","journal-title":"Adv Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e000199","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse Models of Lupus: What They Tell Us and What They Don\u2019t","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded Double Negative T Cells in Patients With Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys","volume":"181","author":"Crisp\u00edn","year":"2008","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2005.02139.x","article-title":"Identification of T-Cell Epitopes on U1A Protein in MRL\/lpr Mice: Double-Negative T Cells Are the Major Responsive Cells","volume":"115","author":"Yang","year":"2005","journal-title":"Immunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00512.2017","article-title":"Podocytes Contribute, and Respond, to the Inflammatory Environment in Lupus Nephritis","volume":"315","author":"Wright","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5361","article-title":"Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, A Novel Inducer of Blimp-1 and Bcl-6","volume":"173","author":"Ozaki","year":"2004","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091777","article-title":"IL-21 Regulates Germinal Center B Cell Differentiation and Proliferation Through a B Cell-Intrinsic Mechanism","volume":"207","author":"Zotos","year":"2010","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/pcmedi\/pbaa001","article-title":"Double Negative T Cells, a Potential Biomarker for Systemic Lupus Erythematosus","volume":"3","author":"Alexander","year":"2020","journal-title":"Precis Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01862.x","article-title":"Aberration of CCR7 CD8 Memory T Cells From Patients With Systemic Lupus Erythematosus: An Inducer of T Helper Type 2 Bias of CD4 T Cells","volume":"112","author":"Sen","year":"2004","journal-title":"Immunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12644","article-title":"The Role of Cytokines in T-Cell Memory in Health and Disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.06.046","article-title":"B-Cell-Intrinsic Type 1 Interferon Signaling Is Crucial for Loss of Tolerance and the Development of Autoreactive B Cells","volume":"24","author":"Domeier","year":"2018","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.3390\/ijms20236021","article-title":"Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e45","article-title":"Crosstalk Between the Producers and Immune Targets of IL-9","volume":"20","author":"Do-Thi","year":"2020","journal-title":"Immune Netw"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, A JAK Inhibitor, Inhibits Human B Cell Activation","volume":"73","author":"Wang","year":"2014","journal-title":"Vitro Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.64","article-title":"B-Cell-Targeted Therapies in Systemic Lupus Erythematosus","volume":"10","author":"Chan","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.03.027","article-title":"Podocyte-Specific JAK2 Overexpression Worsens Diabetic Kidney Disease in Mice","volume":"92","author":"Zhang","year":"2017","journal-title":"Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.04.017","article-title":"The Antiviral Cytokines IFN-\u03b1 and IFN-\u03b2 Modulate Parietal Epithelial Cells and Promote Podocyte Loss: Implications for IFN Toxicity, Viral Glomerulonephritis, and Glomerular Regeneration","volume":"183","author":"Migliorini","year":"2013","journal-title":"Am J Pathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.704526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:49:07Z","timestamp":1629719347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.704526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2021.704526"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.704526","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"article-number":"704526"}}